Immunis is a clinical-stage biotech company developing multi-active biologics with immune modulating factors that can address age-related diseases and immune dysregulation. Immune health and metabolic health decline with age, commonly manifesting as muscle atrophy (sarcopenia), obesity, and reduced physical function. Our investigational IMM01-STEM therapy contains all-natural bioactive molecules published in aged mouse models to improve muscle mass and strength, enhance immune cell recruitment, increase lean mass, reduce fat mass, and increase physical activity. Immunis completed a Phase 1/2a clinical trial testing the safety, tolerability, and efficacy of IMM01-STEM in sarcopenic individuals with knee osteoarthritis and is conducting a Phase 2 placebo-controlled study in adults with sarcopenic obesity.